Engineering the NK1 Fragment of Hepatocyte Growth Factor/Scatter Factor as a MET Receptor Antagonist

Journal of Molecular Biology

Volumn 377, Issue 3, 2008, Pages 616-622

  Youles, Mark ^a   Holmes, Oliver ^a   Petoukhov, Maxim V ^b,c   Nessen, Merel A ^a   Stivala, Simona ^d   Svergun, Dmitri I ^b,c   Gherardi, Ermanno ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c SHUBNIKOV INSTITUTE OF CRYSTALLOGRAPHY   (Russian Federation)

^d NONE

Author keywords

ab initio modelling; HGF SF; MET; receptor antagonist; small angle scattering

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NK1 RECEPTOR ANTAGONIST; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 40849135544     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.01.034     Document Type: Article

References (31)

1. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev., Mol. Cell Biol. 4 (2003) 915-925
2. Borowiak M., Garratt A.N., Wustefeld T., Strehle M., Trautwein C., and Birchmeier C. Met provides essential signals for liver regeneration. Proc. Natl Acad. Sci. USA 101 (2004) 10608-10613
3. Huh C.G., Factor V.M., Sanchez A., Uchida K., Conner E.A., and Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 101 (2004) 4477-4482
4. Chmielowiec J., Borowiak M., Morkel M., Stradal T., Munz B., Werner S., et al. c-Met is essential for wound healing in the skin. J. Cell Biol. 177 (2007) 151-162
5. Christensen J.G., Burrows J., and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225 (2005) 1-26
6. Michieli P., Basilico C., Pennacchietti S., Maffe A., Tamagnone L., Giordano S., et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18 (1999) 5221-5231
7. Mazzone M., Basilico C., Cavassa S., Pennacchietti S., Risio M., Naldini L., et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 114 (2004) 1418-1432
8. Matsumoto K., and Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 94 (2003) 321-327
9. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., and Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (2004) 61-73
10. Cioce V., Csaky K.G., Chan A.M.L., Bottaro D.P., Taylor W.G., Jensen R., et al. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J. Biol. Chem. 271 (1996) 13110-13115
11. Lokker N.A., and Godowski P.J. Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1. J. Biol. Chem. 268 (1993) 17145-17150
12. Schwall R.H., Chang L.Y., Godowski P.J., Kahn D.W., Hillan K.J., Bauer K.D., and Zioncheck T.F. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J. Cell Biol. 133 (1996) 709-718
13. Jakubczak J.L., LaRochelle W.J., and Merlino G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol. Cell Biol. 18 (1998) 1275-1283
14. Chirgadze D.Y., Hepple J.P., Zhou H., Byrd R.A., Blundell T.L., and Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat. Struct. Biol. 6 (1999) 72-79
15. Lietha D., Chirgadze D.Y., Mulloy B., Blundell T.L., and Gherardi E. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 20 (2001) 5543-5555
16. Ultsch M., Lokker N.A., Godowski P.J., and de Vos A.M. Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 Å resolution. Structure 6 (1998) 1383-1393
17. Watanabe K., Chirgadze D.Y., Lietha D., de Jonge H., Blundell T.L., and Gherardi E. A new crystal form of the NK1 splice variant of HGF/SF demonstrates extensive hinge movement and suggests that the NK1 dimer originates by domain swapping. J. Mol. Biol. 319 (2002) 283-288
18. Hartmann G., Prospero T., Brinkmann V., Ozcelik C., Winter G., Hepple J., et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 8 (1998) 125-134 [Published erratum appears in Curr. Biol. 1998 Oct 8;8(20):R739]
19. Lokker N.A., Presta L.G., and Godowski P.J. Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng. 7 (1994) 895-903
20. Kirchhofer D., Yao X., Peek M., Eigenbrot C., Lipari M.T., Billeci K.L., et al. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling. J. Biol. Chem. 279 (2004) 39915-39924
21. Gherardi E., Youles M.E., Miguel R.N., Blundell T.L., Iamele L., Gough J., et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc. Natl Acad. Sci. USA 100 (2003) 12039-12044
22. Svergun D.I. Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys. J. 76 (1999) 2879-2886
23. Green S.M., Gittis A.G., Meeker A.K., and Lattman E.E. One-step evolution of a dimer from a monomeric protein. Nat. Struct. Biol. 2 (1995) 746-751
24. Holliger P., Prospero T., and Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA 90 (1993) 6444-6448
25. Gherardi E., Sandin S., Petoukhov M.V., Finch J., Youles M.E., Öfverstedt L.-G., et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl Acad. Sci. USA 103 (2006) 4046-4051
26. Stamos J., Lazarus R.A., Yao X., Kirchhofer D., and Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 23 (2004) 2325-2335
27. Tolbert W.D., Daugherty J., Gao C., Xie Q., Miranti C., Gherardi E., et al. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc. Natl Acad. Sci. USA 104 (2007) 14592-14597
28. Stoker M., Gherardi E., Perryman M., and Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327 (1987) 239-242
29. Holmes O., Pillozzi S., Deakin J.A., Carafoli F., Kemp L., Butler P.J., et al. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J. Mol. Biol. 367 (2007) 395-408
30. Roessle M.W., Klaering R., Ristau U., Robrahn B., Jahn D., Gehrmann T., et al. Upgrade of the small-angle X-ray scattering beamline X33 at the European Molecular Biology Laboratory, Hamburg. J. Appl. Crystallogr. 40 (2007) s190-s194
31. Konarev P.V., Volkov V.V., Sokolova A.V., Koch M.H.J., and Svergun D.I. PRIMUS-a Windows-PC based system for small-angle scattering data analysis. J. Appl. Crystallogr. 36 (2003) 1277-1282